GVK Biosciences announced that it has been selected as a preferred provider to a consortium of 14 global Product Development Partners (PDPs) for clinical services in Asia. GVK Bio is the only partner that is headquartered in India.
The PDPs, funded in part by the Bill and Melinda Gates Foundation are not-for-profit entities focused on developing new interventions for diseases that are often neglected by mainstream pharmaceutical and biotech companies, such as tuberculosis, malaria, kala-azar, HIV/AIDS, childhood pneumonia, and diarrhoeal diseases. Collectively the 14 PDPs anticipate funding 85 clinical trials in the developing world over the next two years and India features as a key developing world country.
GVK BIO is currently working with some of the PDPs and collaborating with investigators and public institutions in India and Bangladesh to help develop preventive and therapeutic modalities that can eventually be introduced into public health programmes with the aim of dramatically reducing the social and economic burden of these diseases. GVK BIO will collaborate with the consortium as a niche service provider for clinical monitoring, logistics support and safety monitoring apart from overall project management.
“GVK Biosciences is extremely pleased to support the development of health solutions for neglected infectious diseases in India. We are excited to partner the PDPs in advancing their clinical programmes and help address medical and health problems of millions globally,” said Manni Kantipudi, CEO, GVK Biosciences.
GVK BIO is Asia’s leading Discovery Research and Development organisation. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain.